Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model

  • Res Sq. 2020 Oct 8;rs.3.rs-86289. doi: 10.21203/rs.3.rs-86289/v1.
Kyle Rosenke  1 ,  Frederick Hansen  1 ,  Benjamin Schwarz  2 ,  Friederike Feldmann  3 ,  Elaine Haddock  1 ,  Rebecca Rosenke  3 ,  Kimberly Meade-White  1 ,  Atsushi Okumura  1 ,  Shanna Leventhal  1 ,  David W Hawman  1 ,  Emily Ricotta  4 ,  Catharine M Bosio  2 ,  Greg Saturday  3 ,  Heinz Feldmann  1 ,  Michael A Jarvis  1  5  6
Affiliations
  • 1. Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
  • 2. Laboratory of Bacteriology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
  • 3. Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA.
  • 4. Laboratory of Clinical Immunology and Microbiology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institute of Health; Bethesda, MD, USA.
  • 5. University of Plymouth, Plymouth, Devon, UK.
  • 6. The Vaccine Group Ltd, Plymouth, Devon, UK.
PMID: 33052329 DOI: 10.21203/rs.3.rs-86289/v1
Abstract

The COVID-19 pandemic progresses unabated in many regions of the world. An effective Antiviral against SARS-CoV-2 that could be administered orally for use following high-risk exposure would be of substantial benefit in controlling the COVID-19 pandemic. Herein, we show that MK-4482, an orally administered nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model. The inhibitory effect of MK-4482 on SARS-CoV-2 replication was observed in Animals when the drug was administered either beginning 12 hours before or 12 hours following Infection in a high-risk exposure model. These data support the potential utility of MK-4482 to control SARS-CoV-2 Infection in humans following high-risk exposure as well as for treatment of COVID-19 patients.

Products